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ceptually challenging. A desire to provide a complete ranking from best to worst
was observed. The majority (18,75%) of participants indicated a preference for DCE,
as they felt this enabled comparison of alternative full profiles. Of those preferring
BWS (3,50%) indicated the primary reason was related to the ability of BWS to
remove the potential requirement to choose an undesirable characteristic that was
part of a ‘package’, (1,17%) perceived the BWS to be less ethically conflicting, and
(2,33%) perceived BWS to be less burdensome. More participants were consistent
for the DCE (22,92%) than BWS (10,42%) repeated task (p0.002); for BWS, lack of
consistency was not observed to be associated with the choice (best or worst).
CONCLUSIONS: This novel study supports the validity and acceptability of DCE
methods for assessing preferences. The findings relating to the application of BWS
profile methods are less definitive than for the traditional choice task. However,
important avenues for future research to further clarify the comparative merits of
DCE and BWS preference elicitation methods are identified.
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OBJECTIVES: Schizophrenia is a psychiatric illness that associates thought process
disintegration and poor emotional responsiveness. The S-QoL is a self-adminis-
tered questionnaire that assesses quality of life (QoL) among people with schizo-
phrenia. The scale is a 41-item questionnaire with eight subscales (psychological
well-being, self-esteem, family relationships, relationship with friends, resilience,
physical well-being, autonomy and sentimental life). The objective of this study
was to validate the Russian version of S-QoL. METHODS: The scale was of instru-
ment used in a clinical trial with 260 patients. Statistical examinations covered
factor analysis, internal consistency of subscales, construct and discriminant va-
lidity. The reproducibility (Test-retest) was assessed with patients whose clinical
global impression (CGI) improvement score declared unchanged between baseline
and endpoint (10weeks), whereas patients whose health status was improved are
used to evaluate the sensitivity to changes. RESULTS: The sample is composed of
subjects from Russia with 53% of female. Cronbach’s alphas were estimated to be
higher than 0.77. Factor analyses demonstrated the same structure as the French
version. Item internal consistency (IIC) and item discriminant validity criteria were
met for most items (i.e. IIC was  0.40, and correlations between items and their
respective rest-scores in one dimension were all greater than correlations with
another dimension). For the subgroup with no CGI improvement (56 patients out of
260), Test–retest demonstrated a highly correlation (range 0.49-0.79) between the
two assessments. Assessing the sensitivity on the subgroup of 161 patients for
whom an improvement was declared (mean change  1.47), a significant differ-
ence was found for the global score and for all dimensions except the psychology
dimension. CONCLUSIONS: Overall, the S-QoL, which has sound psychometric
properties, is a valid instrument for measuring the disease specific HRQoL of pa-
tients with schizophrenia in Russia.
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OBJECTIVES: Type 2 diabetes mellitus(DM2) and polypharmacy can affect the
health related quality of life(HRQoL). A new 5-level version of EQ5D instrument is
available; it is therefore interesting to evaluate its performance compared to pre-
vious EQ5D-3L. METHODS: Cross-sectional study of baseline data from a cohort of
DM2 patients taking 5 or more drugs (313 patients from a randomized clinical trial
to prevent drug inadequacy in DM2 patients). HRQoL was measured using EQ5D-5L
instrument and compared to previous EQ5D-3L data from a similar population.
Patient socio-demographic data, number and nature of prescribed drugs and
HbA1c serum levels were collected; their associations to variations in HRQoL were
assessed. EQ5D-5L utilities were elicited thru 5L-3L EuroQoL crosswalking value
set. Cronbach’s alpha was used to evaluate reliability of EQ5D-5L in this sample,
and Spearman’s rho coefficient for correlations. RESULTS: Mean age at index date
was 71 years, 57.2% were male and 75.7% were 65 years or older. Mean HbA1c was
7.2%[SD:1.3], 22.4% were taking insulin and 51.6% had a good control of their dia-
betes. On average patients were taking 9.4 drugs[SD:3.8; range:5-23]. Most affected
EQ5D dimensions were mobility and pain/discomfort (more than half of respon-
dents reporting problems). Mean EQ5D utility index was 0.786[SD:0.224; range:
0.224 to 1]. Bad glycemic control (HbA1c7%), use of insulin and a greater number
of drugs were all associated to a poorer HRQoL. EQ5D index was negatively corre-
lated with the number of prescribed drugs(r0.34; p0.01), but no correlation was
found with age or HbA1c. EQ5D-5L showed good reliability (0.77) and less ceiling
(23.3%) and floor (0.3%) effects than 3L. There was a better discrimination capacity
for punctuations in each of the 5 dimensions. CONCLUSIONS: DM2 patients with
polypharmacy showed a diminished HRQoL, negatively correlated to the number of
prescribed medicines; the new EQ5D-5L appears to exhibit better discriminatory
properties than the traditional EQ5D-3L.
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OBJECTIVES: The time trade-off (TTO) and the standard gamble (SG) are two com-
mon tools for the direct elicitation of health utilities, the prevailing quantitative
unit for the evaluation of health-related quality of life (HRQoL) in a given popula-
tion. These tools may be administered to patients for the assessment of their
current HRQoL. Comparisons between TTO and SG outcomes for a patient popula-
tion were explored in the present systematic review of primary evidence from
published studies. METHODS: A systematic review of the literature was under-
taken in Ovid Medline® to identify all publications in English since 1996 reporting
both mean TTO and SG outcomes in the same patient population, on their current
HRQoL. The literature search and data extraction were independently undertaken
by two researchers, using a pre-determined set of inclusion/exclusion criteria to
generate a list of relevant publications, with a third researcher acting as adjudica-
tor in case of disagreement. Excluded were reviews or non-original publications, as
well as publications reporting health utility outcomes of hypothetical health states.
Data were analyzed on study arms (studies) for differences and/or correlation be-
tween the TTO- and SG-derived utilities. RESULTS: The initial literature search
identified 170 articles which yielded 56 relevant publications encompassing 26
disease categories, 79 studies and a total of 11,090 patients. The most common
disease category, discussed in 18 studies covering 2,258 patients, was ocular dis-
ease. The overall weighted mean utility scores were 0.82 and 0.85 for TTO and SG
respectively, with 61% of studies reporting higher utility scores with SG and 6%
equal results. Overall, 22% and 33% of studies displayed greater than 10% absolute
and relative difference between the two measurement tools, respectively. Spear-
man’s rho yielded significant positive correlation (r  0.586). CONCLUSIONS: The
majority of studies displayed little difference in scores between TTO and SG, with
significant correlation observed overall.
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OBJECTIVES: To explore the ability (validity) of the OAB-V8 screening scale to pre-
dict changes in patient’s HRQoL and severity of symptom bother (SB) in subjects
with symptomatic OAB treated with antimuscarinic drugs in daily practice in clin-
ics of Urology. METHODS: Patients, both genders, 18 years, with symptomatic
OAB [score8 in OAB-V8 scale] and able to understand and fill-in PRO instruments
written in Spanish were enrolled in this study. The culturally adapted and vali-
dated Spanish version of OABq-SF was administered twice 3 months apart to pa-
tients recruited consecutively at clinics of Urology all over the country and who
were prescribed a treatment with an antimuscarinic drug according to usual prac-
tice. Patients were compared in the OABq-SF: SB and HRQoL scorings. To test the
predictive validity of the OAB-V8 scale, baseline scores were included in multivar-
iate regression models along with age, symptoms duration, age at the initiation of
symptoms, body mass index, and generic HRQoL (assessed with EQ-5D) as covari-
ates to predict changes in OABq-SF dimensions from baseline to follow-up at
3-months period. RESULTS: The study enrolled 246 OAB symptomatic patients
(mean age 57.7 years, 67% women, 99% Caucasian, 37% active workers, 36% pri-
mary schooling). OAB-V8 scores significantly correlated (Pearson’s r coefficient)
with OABq-SF domains;0.790 and0.659 for SB and HRQoL domains, respectively
(p0.001 in both cases) indicating a possible linear relation. Multivariate regression
models showed OAB-V8 baseline score being able to predict changes in both do-
mains of the OABq-SF; R2 0.212 and 0.162 in severity of SB and HRQoL, respec-
tively. OAB-V8 coefficients were significant in the two models with  coefficients of
0.421 (p0.001) and 0.340 (p0.001), respectively. CONCLUSIONS: The OAB-V8
scale provided evidence of predictive validity of self-assessment quality-of-life and
severity of symptoms bother changes in patient with OAB treated with antimus-
carinic drugs in routine medical practice.
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OBJECTIVES: The time trade-off (TTO) and the standard gamble (SG) are two meth-
ods for the direct measurement of health-related quality of life (HRQoL) in a pop-
ulation. These tools may be used not only in patients but also to evaluate the
general public’s preference for a particular health state. The purpose of this study
was to undertake a systematic review of the literature comparing TTO and SG
outcomes for the general population. METHODS: Ovid Medline® was scoured to
gather original studies published in English since 1996 reporting both mean TTO
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and SG outcomes from members of the general public who were asked to evaluate
hypothetical health states. Two researchers, with a third acting as adjudicator,
independently undertook the review of the literature, the inclusion/exclusion pro-
cess and data extraction. Statistical analyses were performed on study arms (stud-
ies) for differences and/or correlation between utility scores derived from TTO and
SG. RESULTS: Of the 170 publications yielded by the initial literature search, 19
pertinent articles were included in the present analysis, covering 24 disease cate-
gories, 77 studies and 17,515 subjects. The overall weighted mean health utility
scores were 0.82 with TTO and 0.83 with SG. Studies reporting a greater than 10%
absolute difference between the two measurement tools represented 13% (k10),
while 22% reported greater than 10% relative difference (k17), 51% reported over-
all higher utility scores with SG (k39) and 13% reported equal scores (k10). The
most common disease category, discussed in 8 studies covering 2,490 participants,
was ocular disease. Spearman’s rank test yielded significant positive correlation (r
 0.924). CONCLUSIONS: The majority of studies displayed little difference in
scores between the TTO and SG methods collected from the general public. A high
positive correlation was observed between utility scores reported by the two meth-
ods.
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OBJECTIVES: As the patient perspective becomes increasingly critical in this era of
patient-centric care and patient cost-sharing, a better understanding of research
methodologies and their impact on validity of responses is required to assess the
growing body of patient research. Increasingly, researchers are able to leverage
technology in order to access patient panels; however, questions remain as to their
robustness and representativeness. Here, we review the underlying survey re-
sponse differences obtained from both nonprobability and probability-based pa-
tient samples accessed via online survey panels and the potential impact to pa-
tient-centered research. METHODS: A review was conducted of a mixed-method
patient survey examining self-identified smokers and motivation to quit, which
utilized both probability and nonprobability samples. Survey results were com-
pared from 1,427 probability and 5,425 nonprobability patient samples. The prob-
ability sample was obtained from a statistically valid online panel, representative
of the US population. Survey responses between groups were compared using
Student’s t-test and Chi-square tests. RESULTS: The probability sample reported
smoking more cigarettes per day (p0.001) and were more likely to report smoking
every day (p0.001). Additionally, patients in the nonprobability sample were more
likely to report that they planned to quit smoking in the next 30 days (p0.001) and
that they had made an attempt to quit smoking in the past 6 months (p0.001).
CONCLUSIONS: Survey results for patient reported outcomes studies obtained
through nonprobability sampling varied significantly from those obtained through
probability sampling; and response variation is unpredictable. Calibrating non-
probability samples with probability samples using specific screening questions
may minimize bias in the resulting estimates in the larger combined sample. In
order for patient-centered outcomes research to play a meaningful role in health
care policy and decision making, rigorous probability sampling methodologies
must be applied in order to allow interpretation of results with high confidence.
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OBJECTIVES: This study assessed the measurement properties of the Functional
Assessment of Cancer Therapy – Anaemia (FACT-An) for use in patients with anae-
mia associated with chronic kidney disease (CKD). METHODS: FACT-An data were
collected in an open label dose titration, randomised phase 2b clinical trial (study
FGCL-4592-041) with non-dialysis CKD patients with anaemic stages 3 and 4.
FACT-An was completed at baseline, and treatment Weeks 9 and 17. RESULTS:
Data from 145 patients were analyzed. Average age was 64.4 yrs (SD11.3), 63%
were female. Average hemoglobin (Hb) level was 9.7 g/dL (SD0.7), 11.4 (SD1.2),
and 11.7 (SD1.1) at baseline, Weeks 9 and 17, respectively. Internal consistency
and test-retest reliability were 0.70 for all subscales, except the Emotional Well-
being subscale (EWB). Convergent validity was shown by correlations between
FACT-An Total score, Anaemia subscale, and Fatigue subscale with SF-36v2 Phys-
ical Functioning (0.57-0.61) and Vitality (0.73-0.76). Correlations were low between
FACT-An Total score, Anaemia subscale, and Fatigue subscale and Hb level at
baseline (0.14-0.15), but increased at treatment Weeks 9 (0.16-0.20) and 17 (0.23-
0.26). A responder analysis showed that FACT-An Anaemia and Fatigue subscales
were responsive in detecting small but significant changes in Hb level at week 9.
The FACT-An Total score, Anaemia subscale, and Fatigue subscale, were able to
detect SF-36v2 Vitality score increase of 5 points from baseline to Week 17. Based
on distributional and anchor-based methods, the minimally important difference
was estimated as score change of 8-10 for FACT-An Total score, 4-7 for Anaemia
subscale, and 3-5 for Fatigue subscale. CONCLUSIONS: This study shows the
FACT-An Total score, Anaemia subscale, and Fatigue subscale to be a reliable, valid,
and responsive instrument for CKD patients with anaemia. Results on the ability to
detect Hb changes were limited due to the narrow range of Hb values available in
this study.
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OBJECTIVES: To test the face and content validity of the US-English version of draft
patient satisfaction questionnaires for subcutaneous (SC) (referred to as the ‘RASQ-
SC’) and intravenous (IV) (referred to as the ‘RASQ-IV’) administrations of treat-
ment for Non-Hodgkin’s Lymphoma (NHL).METHODS:Qualitative interviews were
conducted with 10 US-English speaking adults from 2 US cities who had received an
IV administered NHL treatment in the past 4 weeks. The interviews began with a
concept elicitation (CE) section which focused on eliciting information relating to
the patients’ IV treatment experiences and perceptions of satisfaction and impacts
of a SC administration. Patients were then shown a short video showing the SC
administration process. The draft satisfaction questionnaires were then cogni-
tively debriefed (CD) using a “think-aloud” exercise to explore the content validity
of the RASQ-SC and the RASQ-IV. Interview transcripts were thematically analysed
using Atlas.ti software employing a grounded theory approach. RESULTS: Patients
were aged 43-77 years and 70% were female. Seventy percent of patients were
diagnosed with diffuse large B-cell lymphoma and 30% with indolent B-cell, stages
ranging from 1-4. Qualitative analysis demonstrated that the RASQ-IV and
RASQ-SC have excellent coverage of the treatment satisfaction and impact con-
cepts reported by patients in the CE section and during the debriefing of the RASQ-
IV. Patients’ demonstrated a good understanding of all item wording, instructions,
response scales and the recall period in the RASQ-SC. A small number of minor
revisions were made to further improve patient understanding and aid consistent
interpretation. CONCLUSIONS: The findings indicate that overall the RASQ-SC and
RASQ-IV had strong face and content validity and, following some minor revisions,
will measure the key differentiators that are important and relevant for the differ-
ent NHL treatment administration options. The instruments are appropriate for
inclusion in trials as secondary or exploratory endpoints.
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OBJECTIVES: The FDA’s Guidance for Industry, on Patient-Reported Outcome (PRO)
Measures: Use in Medical Product Development and to Support Labeling Claims
noted that validation of PRO in adults does not provide evidence for pediatrics[1].
PRO development and validation in pediatrics involves different processes, as out-
lined in a forthcoming ISPOR Good Research Practices report (GRPr)[2]. The research
objective was to consider recently implemented qualitative research strategies in
pediatrics aged 12-17 years with an orphan disease to inform the best practices for
PRO development in this population. METHODS: Consistent with the GRPr for PRO
research in pediatrics, focus groups (FGs) and individual interviews (IDIs) were
planned in Germany, Switzerland, Turkey, the UK and the United States (US). Dis-
cussions with local physicians preceded recruitment, which served as an opportu-
nity for them to relay parents’ concerns and reveal variances among adolescents
with an orphan disease. Informed consent and EC approval were obtained. A 2 x 2
(gender: female, male x age cohort: 12-14, 15-17) design of focus groups accommo-
dated social differences. RESULTS: Adolescent recruitment is complex, especially
in an orphan disease sample. Identifying eligible adolescents with an orphan dis-
ease who may remain asymptomatic until later in life was challenging, and parents
were not always willing to provide consent. Consequently, we conducted more IDIs
and fewer FGs than planned. Although US-based ethics review was a standard
process, European ECs had no formal process for concept elicitation and all issued
tacit or explicit waivers. CONCLUSIONS:Qualitative research for PRO development
in adolescents with an orphan disease requires a unique approach. We recom-
mend a 3-4 month lead time from protocol finalization to meeting commencement.
When designing protocol and recruitment strategies, researchers should ensure
adequate pediatric protections and seek EC approval. ECs should develop review
processes specifically for future PRO development research.
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Patient-reported outcome (PRO) assessment for pediatric populations is complex.
Potential variations in cognitive development and disease impact/treatment
across a wide age range present challenges for PRO assessment. Epidermolysis
bullosa (EB) is a rare, incurable genetic skin disorder primarily affecting children.
Common clinical manifestations are skin blistering and chronic wounds. Children
with EB and their families face numerous health-related quality of life (HRQOL)
issues. OBJECTIVES: To identify and evaluate HRQOL measures for use with chil-
dren (aged 3 years) with EB. METHODS: A structured PubMed search was con-
ducted using Medical Subject Heading search terms. Of the 143 abstracts identified,
40 were appropriate for further evaluation; 33 articles underwent full-text review.
Content validity and other psychometric properties of identified HRQOL measures
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